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1Chapter
Developing Countries Can 
Innovate and Produce Vaccines: 
The Case of Butantan in Brazil
Isaias Raw
Abstract
Since the  introduction of vaccines, governments learn that they are the most 
efficient and inexpensive tool to avoid the spreading of infectious diseases. It 
resulted in the creation of public research institutes to develop new vaccines, 
which gave birth to the vaccine industry, that is, growing in size by acquisition 
of competitors, which estimate that in 2019 they will sell $58 billion, where 
developing countries represent 80% of the world population, submitted to be 
dependent of production and prices from large producers. Incapable or not will-
ing to assume the responsibility to produce, accept to purchase vaccines in bulk 
for filling and labeling as “producers.” Butantan, a public not for profit institute 
became the first producer of specific anti-venoms and anti-rabies sera. In 1985, 
Butantan Center of Biotechnology attracted 25 young PhD, which accepted to 
carry on inovations and technical developments, setting dedicated plants to 
produce vaccines at affordable cost, aiming self-sufficiency to distribute free 
through the Ministry of Health. This chapter describes problems and solutions 
that must be faced to produce vaccine at a cost that developing countries can 
afford.
Keywords: vacines control epidemics, developing coutries 80% of world population, 
developing countries self-sufficiency, Butantan from innovation to production, 
anti-venonms and anti-toxinas, encloses production plants, pertussis reduction by 
DTP vaccine, whole pertussis low in LPS, MPLA from B pertusis as adjuvant, MPLA 
adjuvant reduce ¼ influenza doses an price of vaccine, vitamines A,D,E, riboflavin 
as adjuvants, pneumococcus-PSAP3 reduce cost of pneumo vaccine, plasma fractions 
not for sale, lung surfactant saves neonatals
1. Institute Butantan—research, process development, and production
1.1 Antivenoms and antitoxins
Antisnake venoms were the strength of Instituto Butantan and its priority 
[1–4]. At the New York World Fair, Vital Brazil saved the life of an employee 
of the Bronx Zoo bitten by a rattlesnake, which induced President Theodore 
Roosevelt pay a visit to Butantan in 1915. In 1983, Butantan sera production situ-
ation was scary: venoms were collected from snakes and administered to horses. 
The horses were bled and their blood collected in rusted milk drums, precipitated 
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with ammonium sulfate, concentrated using a dirty towel, diluted and kept in 
large bottles until they “mature,” and covered with mold! Probable other develop-
ing countries producers used the same ancient manufacturing process. Changing 
the production technology was the first goal of a recent Ph.D. group of research-
ers supported by the staff from the production laboratories under my supervision 
(Figures 1–6).
The first idea was to replicate the milk industry profile, creating a “hands-off” 
fully enclosed system using large stainless steel tanks and an industrial plate cen-
trifuge. After snake venom inoculation, horse blood was collected in a 7-liter sterile 
bag with anticlotting solution, stirred, and kept in a cold room overnight. After 
plasma been removed, the settled cells were isotonic saline solution suspended and 
transferred to a connected-enclosed-4-liter bag to be returned to the same horse, 
characterizing plasmapheresis process and thus allowing repeated blood collection 
at short intervals.
The separated plasma was submitted to a complex process for immunoglobulin 
purification, began by precipitation by ammonium sulfate, followed by filtra-
tion, pepsin treatment (to remove the Fc portion of immunoglobulin to prevent 
complement activation), heath treatment, addition of caprylic acid to inactivate 
lipid-enveloped virus, finishing by an ion-exchange chromatography, which 
also removes viruses and other microorganisms. After sterile filtration, the final 
product was tested for neutralization potency and formulated to guarantee efficacy 
and safety.
Along 1985 to 2009, the production of antibothropic, anticrotalic, antielapidic, 
antilonomia, and combined antiarachnidic with other antivenomous insects sera 
reached about 700 million vials. The technology and the enclosed system were the 
model basis for the production of antitetanus, antidiphtheria, antibotulinic, and 
antirabic sera for human use. The antisera are usually presented in 40–100 ml vials 
diluted with isotonic sodium chloride solution, to be administered intravenously. 
Vials are kept refrigerated, and the freeze-drying process started to be introduced to 
avoid losses. Butantan supplies the demand of the Ministry of Health and began to 
export antisera to Latin America, some Africa countries, India, and even to attend 
the request of some countries in Europe and Australia. It was an unusual experience 
in learning by doing.
Figure 1. 
Partial view of plasma fractionation production plant of antivenoms and antitoxins (Instituto Butantan 
Foundation).
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Figure 2. 
Tetanus, diphtheria, and pertussis enclosed production systems.
Figure 3. 
Coverage of DTP vaccination and incidence per 100,000 inhabitants of pertussis, tetanus (except neonatal), 
and diphtheria in children below 1 year of age in Brazil from 1990 to 2008.
Figure 4. 
Partial view of influenza production plant (Instituto Butantan Foundation).
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Figure 5. 
Partial view of the hepatitis B production plant (Butantan institute foundation).
Figure 6. 
One of the larger chromatography columns of plasma fractionation plant (Instituto Butantan Foundation).
5Developing Countries Can Innovate and Produce Vaccines: The Case of Butantan in Brazil
DOI: http://dx.doi.org/10.5772/intechopen.83351
2. Diphtheria tetanus and pertussis (DTP) vaccine
The gained experience in innovation, clinical testing, production development, 
and full production of antisera pushed our team to move next step into vaccine 
development, maintaining the dedicated enclosed plants, which guarantee hands 
off from the production staff [5–10].
The tetanus and diphtheria toxins production happened in enclosed large-
scale cultivation systems as well as with the Bordetella pertussis strain (bioreactors 
180–500 l). One observed particularity is that tetanus culture requires a vibromixer, 
a special device to promote the culture liquids shaking and not stirring. Bacteria 
were removed by tangential flow filtration, and toxins secreted in the media were 
purified by chromatography and finally detoxified basically following WHO 
recommendations.
A major concern was pertussis, a very common infant infection disease known 
as whooping cough. It can be fatal as a result of a variety of toxic substances from 
the classes of exotoxins and endotoxins. Among them, pertussis toxin, tracheal 
cytotoxin (that affect the respiratory epithelium), dermonecrotic toxin, and adeny-
lyl cyclase (that inhibits phagocytosis) are the most studied and important.
We were able to select a strain of B. pertussis to produce an effective vaccine 
with mild reactogenicity and called it as whole cell pertussis (wP). After intro-
duction of Butantan DTP vaccine (in between 1990 and 2009), the Ministry of 
Health reported that the incidence of pertussis infection had decreased from 
about 11/100.000 to 1/100.000, with practically no adverse reactions after vaccine 
administration. Around 70 million children were vaccinated.
The safety of Butantan’s pertussis component of its DTP vaccine contrasted 
with the safety of DTP vaccine produced in Japan and in other countries. These 
vaccines are known as whole cell pertussis (wP). The development of an acel-
lular pertussis (aP) vaccine based on purification of some virulence factors as 
pertussis toxin was a logical pathway. The acceptance of aP was achieved by 
most developed countries. These vaccines contained pertussis toxin, filamentous 
hemagglutinin (FHA), fimbria protein (FIM), and some pertactin. The aP vac-
cine required isolation and purification of all components, which raised its price 
from about US$ 0.16 to US$ 1.60, making it not accessible to the majority of the 
population from the developing countries. In 2013, CDC made a survey in the 
US and found that the aP confers a short protection, resulting in about 40.000 
pertussis cases/year [11].
DTP vaccination scheme is usually carried out at 2, 4, 6, 18, and 48 months 
of age. One last booster occurred 10 years later. Thus, just for four DTP vaccine 
doses, replacing the DTwP by DTaP would represent an increase in cost of at 
least US$ 6.40 per capita, which is out of reach for poor countries. Even though a 
Brazilian publication [12] incited the use of aP for universal vaccination in Brazil 
at a “modest” cost of US$ 15,590 per life year saved, DTwP vaccination would cost 
100x less.
There are other concerns for the use of aP [13]. Fetus and newborns may be 
exposed to pertussis infection before they are protected against it. Immunization 
occurs by three doses of DTP at 2–4–6 months of age. It is estimated that 45% of 
infant mortality occurs before they reach 5 years and is mainly concentrated before 
6 months. This leads the idea to vaccinate pregnant women in the third trimester, 
generating maternal antibodies to be transferred to the babies by breast feeding. It is 
still necessary to fully investigate the safety of this type of vaccination to guarantee 
that there are no effects on the fetus [14–16].
Butantan has proposed an alternative for aP vaccine. It developed a process to 
remove the lipopolysaccharide (LPS), the most reactogenic component of the outer 
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membrane of most gram-negative bacteria, without breaking the bacterial mem-
brane, producing a whole cell pertussis vaccine low in LPS (wPlow). This vaccine 
was retested at Nederland Vaccine Institute [8] and currently is under additional 
clinical trials, as required by the Brazilian regulatory agency, to replace wP in our 
DTP, without increasing cost. Furthermore, the isolated LPS can be hydrolyzed to 
obtain monophosphoryl lipid A (MPLA), a power vaccine adjuvant.
Other alternative for the vaccination of the newborn is BPZE1, a live genetically 
attenuated pertussis, developed by Pasteur-Lilly by inactivating pertussis toxin, tra-
cheal cytotoxin, and dermonecrotic toxin [17–18]. This vaccine will be administered 
in newborns as a single-dose nasal vaccine. Its clinical assay is being proposed.
3. Hepatitis B
Butantan developed a recombinant hepatitis B vaccine by genetic engineering, 
based on the hepatitis B surface antigen (HBs) and expressed in the yeast Hansenula 
polymorpha with a good yield [19–25]. The vaccine was tested in adults, adolescents, 
and newborns with the cooperation of the Institute of Tropical Medicine, the 
Medical School in Campinas and Oswaldo Cruz Institute [19–22]. It was the first 
recombinant vaccine developed in Brazil, approved and accepted for newborns 
by the regulatory authority in 1997. A total of 260 million doses were produced 
between 1997 and 2009, delivered to the Ministry of Health that distributed to all 
States for free administration to newborns, children, and adults. No significant 
adverse events were reported. The potential use of hepatitis B vaccine or antibody to 
treat chronic hepatitis B must be explored in the future [23].
Other new developments have been planned like the vaccine association with the 
adjuvant MPLA to reduce its concentration/dose (at least by fourfold as some assays 
have showed). These results consequently increase the vaccine’s potential installed 
capacity without increasing the vaccine cost. A new genetic construction to express 
the preS antigen (the N-terminal polypeptide in the large (L) HBs antigen associ-
ated with virus attachment to the host cell receptor and membrane fusion during 
entry) was implemented considering the about 10% of nonresponsive adults. The 
use of the regular vaccine and the preS vaccine to treat chronic infection was also 
considered, but it was not yet tested. The success of the regular vaccine to protect 
newborns postponed the materialization of the last proposal.
Recently, a study was conducted in Brazil revealing that hepatitis B is not the 
prevalent strain causing hepatitis, with variation in different regions. Hepatitis 
A represents 58.7% followed by hepatitis D and F (23.4%), while B, C, and G are 
minor23-24. In a world overview, B/C relation represents 60% [24]. It is estimated 
that there are 5.000 cases of hepatitis C. The Ministry of Health is trying to cure 
with a patented drug that inhibits replication of the virus, sofosbuvir combined 
with daclatasvir, at a cost of about US$ 9000 per patient. The Instituto Oswaldo 
Cruz is trying to market a generic drug for four times less. The right of the Brazilian 
Ministry of Health to be able to supply the drug for all is being questioned by the 
patent holders, although it was accepted during the AIDS epidemics.
4. Butantan legacy, influenza, and adjuvants
Butantan assumed a national leadership in vaccine production in 2007, with 
dedicated plants for diphtheria, tetanus, pertussis, and hepatitis B [26–32]. 
Going from the innovation all the way to production, Butantan provided the 
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Society’s demand to control wide spread infections, delivering vaccines free of 
charge to all population at risk, at acceptable cost to the resources of the Ministry 
of Health.
The public memoir goes back to 1918 when the “Spanish flue” reported 116.777 
cases in city of São Paulo and killed 5.330 people. Those who could afford or have 
family elsewhere fled the country, leaving the streetcars to transport bodies to 
be buried in common graves. Government and Society respected the transla-
tion of “innovation” into vaccines and sera, safe, and efficient. Developing and 
manufacturing vaccines were different from buying bulks from large companies to 
formulate, fill, and label as made in the other countries. This situation was named 
at WHO meetings, the “coca-cola” model: buy bulk, dilute, and label made in the 
countries.
With the few vaccines and antisera mentioned, between 1985 to 2009, 
Butantan was able to produce about 720 million doses of effective and safe vac-
cines, representing 80% of the vaccines really made in Brazil, receiving for this 
about 40 honors, medals, and public grants. This was made possible by creat-
ing Butantan Foundation, a not-for-profit body that could operate as a private 
organism, by  passing the Government rules, which would make impossible to 
buy reagents,  supplies and equipment, maintain or built new labs and dedicated 
production plants, hire, and trend in service, the staff, to operate the plants, 
without the constrains of public rules, which were not adapted to solve public 
emergencies.
The next priority was flu epidemic risk. The “Spanish flu” reached Brazil in 
1918 killing about 35,000 people. US-Barda realized, as pandemic spreads, that the 
total world production vaccine plants against flu could not supply the demand for 
vaccines, as the virus serotypes change each year and stocks could not survive and 
be used for the next epidemics.
Butantan seasonal or pandemic flu first action experience was to set a pilot 
laboratory to maintain and replicate influenza strains certified by WHO and 
CDC for production, and to train the staff for produce. A control lab to test 
and certify vaccines was installed. The State and Federal Government granted 
10 million dollars to build the production lab, ordered when possible custom-
made equipment (like the machine to destroy the infected shells that was built 
in Brazil). A central formulation plant was constructed and equipped with a 
modern automated filling line, to wash and sterilize vials, fill cap, and label vials, 
with filling capacity of 28,000 vials per hour, containing 10 doses each. A second 
automated filling system was added to cover for all the vaccines produced. Flu 
vaccine was cultivated in fertilized chicken eggs and, after extensive purification 
steps, was transferred for formulation and filling. C. Merrieux (latter Sanofi) 
extended its help to Butantan, following the plant construction and installa-
tion, and inspecting to be sure of our suppliers of chicken eggs comply the rules 
established by WHO.
The first formulated vaccines produced were taken to Merrieux’s labora-
tory to be inspected and tested for the demanded requirements of the European 
Community. Butantan transported the vaccines using cold trucks to the central 
stock of the Ministry of Health in charge to vaccine distribution to all the state 
centers, which transfer them to municipal facilities during vaccination. To attend 
actual Brazilian yearly demand, about 100 million flu vaccine doses are necessary 
and it is not an easy task to achieve. It took a few years until the regulatory agency 
approved Butantan’s vaccine, while Sanofi assumed an agreement to meantime 
supply the vaccine in bulk for formulation at Butantan. We reached, in 2017, the 
production of 60 million doses of flu vaccine given to children, young adults, 
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pregnant women, and people above 60 years or with special health problems, doc-
tors and nurses.
About 5 million Brazilians live above the equator line and, by mistake, they 
received the same Southern vaccine, in the same date. It was clear that they were 
vaccinated after the top of the flu season was over, and they were not protected 
[25]. The solution was to use part of the year to produce Northern flu vaccine to 
supply the population in the North. As the sole production plant in Latin America 
(other than a Sanofi plant that provides bulk to Birmex in Mexico), the excess vac-
cine production should be offered to PAHO rotating fund, solving the demand of 
vaccine influenza for Venezuela, Colombia, and Central America (some countries 
use North and other Southern vaccines).
Butantan became interested in using adjuvants for vaccine production, if 
they would guarantee more vaccines doses using the same facilities and thus 
reducing their costs. The first attempt, in 2002, was to use a formulated vitamin 
A in oil as a potential adjuvant to DTP [5]. The production of flu vaccine allowed 
Butantan to look into adding adjuvants to reduce antigen/dose, increasing the 
plant capacity and reducing the purchase of fertilized eggs. A ready formulated 
adjuvant was offered by one of the large producers of vaccines, but that would 
give to this company the control of the Brazilian market. We considered formu-
lating our adjuvant using squalene as a component, but the supplier advertised 
that squalene was restricted to competitors. Squalene plus tocopherol (adjuvant 
system ASO3) resulted in some cases of narcolepsies in Scandinavia and China, 
attributed to a deficiency of hypocretin secretion by hypothalamic neurons 
[27–28]. ASO3 comes in two formulations, ASO3A with 11.86 mg/dose and ASO3B 
with 5.93 mg/dose [30]. In our assays, testing vitamins as adjuvants [29], we 
also included and studied tocopherol present in several multivitamins sold over 
the counter, and known to be toxic to monkeys. We developed the production 
of Bordetella pertussis monophosphoryl lipid A (MPLA), as a byproduct of the 
production of the low reactogenic pertussis vaccine (Plow). This MPLA has 
been shown to be a powerful adjuvant. We also tested vaccines with vitamins as 
adjuvants, which are produced in large volume as nutritional compounds. Testing 
27 adjuvant combinations [5, 31–32], we concluded that the most promising was 
MPLA with the classical Al(OH)3 [33]. Riboflavin and folic acid may act as a 
bridge to mucosal-associated invariant T cells (MAIT) and the major-histocom-
patibility-complex-related molecule MR1 [34]. We tested riboflavin combined 
with MPLA and a trivalent influenza vaccine, and we found a high increase in 
antibody titers [31].
We found that addition of adjuvants to influenza vaccine allowed a decrease 
in the usual dose of 15–3.75 μg. The adjuvant addition increased the vaccine 
production by 4-fold per egg, for the four split virus: A H1N1, H5N1, H3N2, and 
even H7N9, a new serotype spreading present in the vaccine. We also developed 
a whole virus vaccine technology in 2010 [35], recently being tested by several 
large-scale vaccine producers. Whole virus represents more than double produc-
tion of vaccine/egg, as compared with split virus, and may decrease produc-
tion cost by a factor of 2-to 5-fold, which would make preventive influenza 
vaccination affordable to developing and poor countries. In the whole virus, 
nucleoprotein is present, and they activate toll-3, toll-7, and toll-9 receptors of 
the host cell, explaining the higher immune response, but also produces anti-
bodies that cross react with hypocretin receptor 2, which will require careful 
investigation before whole virus influenza vaccine is approved. There are results 
suggesting that the role of vaccine adjuvants like vitamin A and E increases the 
IgG1 response as high as squalene. Vitamin D was shown to modulate influenza 
immune response [35].
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5. New vaccines under development at Butantan
5.1 Haemophilus influenza B
Vaccines against Haemophilus influenza B are based on polysaccharides. The 
technologies for the production and the conjugation of the polysaccharides with the 
carrier protein were developed by Butantan, from 2007 to 2012. It is ready to move to 
full-scale production [36–38]. This product will allow to simplify vaccination of new-
borns, by combining in a single vial a pentavalent vaccine, DTwPlow, Hepatitis B and 
H. influenza B, all produced with our own technology, which depends on building a 
GMP-dedicated lab for Haemophilus production, evaluating trials and registration.
5.2 Rotavirus vaccine
An agreement NIH-Butantan authorized Butantan to produce the pentavalent 
rotavirus vaccine. Butantan was the first to produce experimental lots for a clinical 
trial phase I, which was conducted with good results [39]. The phases II and III trials 
were not yet authorized by Anvisa, but opened for the GSK tetravalent vaccine, using 
Biomanguinhos as an importer. This occupied the Brazilian public market for about 
six years. A new vaccine trial comparing with the GSK vaccine was planned with 
NHI, but the previous Butantan board of directors and management did not act.
5.3 Dengue vaccine
An agreement with NIH allowed Butantan to start a pilot production of dengue 
vaccine. Trials at School of Public Health of Pennsylvania were successful, but the 
clinical trial of Butantan vaccine was delayed 2 years by ANVISA, while allowed 
Sanofi to test their tetravalent vaccine in Brazil. After two years delay, Butantan is 
conducting the clinical tests in different regions of Brazil, using pilot-scale vaccines 
produced by Butantan. Clinical tests about to finish slowed down by an unusual 
decrease in the incidence due to unexpected weather changes. Production plant 
building is about to be completed by 2019. Meantime, Sanofi vaccine tested in Brazil 
will not be used and was not approved by any other countries due to serious adverse 
reactions. Even so, the Brazilian State of Paraná purchased the Sanofi dengue vac-
cine, while Philippines sued Sanofi for its adverse events.
Vaccine Age Produced by
Hepatitis B birth: 1, 6 months Butantan
BCG intradermal
[BCG-S1pertussis]
birth Ataulfo Paiva
Butantan
DTwP + HiB
[DTwPlow + HiB]
2, 4, 6 months Imported
Butantan
Oral polio 2, 4, 6, 15 months Biomanguinhos/GSK
[Rotavirus] 2, 4 months Imported
Butantan-NIH
Pneumococcal conj
10 valente
2, 4, 6, 10 months Imported
Butantan
Meningitis C conj 3, 6, 15 months Imported
Yellow fever 9 months Biomanguinhos
[vaccine]: under development.
Brazilian vaccination schedule.
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5.4 DTwPlow and MPLA
The production plants developing antigens diphtheria and tetanus were 
supposed to be renovated to comply with WHO recommendations and require-
ments by ANVISA. Thus, at the moment, the production has been stopped. 
Meantime, we invested in the development of large-scale technology for MPLA 
from B. pertussis, expected to be used as an adjuvant for influenza and hepatitis 
B vaccines.
5.5 Pneumococcal vaccine
To replace a mix of 13 to 20 serotypes of pneumococcus, Butantan developed a 
vaccine based on recombinant pneumococcal surface protein A (PspA) from three 
different strains, making production easier and less expensive [40–42].
5.6 Modified BCG
By genetic engineering, a BCG expressing pertussis S1 protein was obtained. 
It was shown to be more immunogenic than the regular BCG and more effective 
in a mouse model of bladder papilloma. With this, new BCG Butantan intends to 
perform proper human trials and return to produce BCG to take place at Ataulfo 
Paiva Institute that is closing its operation [43–47].
5.7 Rabies vaccine for human use
Rabies vaccine was produced by Butantan for many years, using basic Pasteur 
process and using suckling mice to isolate brains [48–49]. The rabies virus inac-
tivation used an ultraviolet lamp. This type of production was abandoned as the 
Ministry of Health requirement was to immunize each year about 42,000 domestic 
dogs. A new process was developed using Vero Cell in a serum-free media, fol-
lowed by inactivation, to be used in human who had been bitten by suspected dogs 
[48–50]. The production and control of this vaccine limit the production to a few 
producers, being an expensive vaccine. Butantan invested in a large plant to where 
production is expected to be transferred in 2019.
6. Other process and products under development at Butantan
6.1 Plasma fractionation
According to the Brazilian Constitution, blood cannot be purchased from donor, 
nor its fractions sold; thus, plasma fractionation must be a public not-for-profit 
operation. Butantan did not have access to the plasma, but developed a process for 
hemoderivatives obtaining from human placenta extracts, establishing technologies 
to separate a series of proteins at high purity. The process allowed to isolate and 
purify albumin, immunoglobulin G, and some enzymes of potential interest for 
medical use [50–54]. When we got access to bags of human blood, we developed the 
purification process of factor VIII [55].
Butantan has worked in the development of a modern plant, replacing the Cohn 
method by sequential chromatographic steps, thus avoiding denaturation of frac-
tions with potential clinical use caused by ethanol precipitation. The State of São 
Paulo with a few other states collected a large part of the human plasma collected in 
Brazil.
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The Government of São Paulo provided funds to build a plant and purchase 
special equipment. The plant was built and part of the equipment acquired. It was 
planned to be an automatized facility, and a company with expertise was contracted 
to design a computerized central of control system that would direct the simultane-
ous steps of the process. This has already represented a partial investment of about 
US$ 200 million, while we maintained a small pilot plant to test every step of the 
complete process for purification of albumin, immunoglobulin, and coagulation 
factors. The scientific project started at Butantan in collaboration with Pharmacia, 
which was willing to participate in developing a plant to process about 150,000  
l/year, purifying about ten different proteins.
Among other reasons, the project stopped after Pharmacia was sold to GE, which 
lack expertise and did not have the same interest in this project, which could be 
transferred to other countries, and Butantan would open its plant to train operators. A 
second impediment became the interest of a few large-scale plasma fractionation for-
eign companies, which would like to process Brazilian plasma in their existing plants, 
where Cohn method was utilized to supplement final purification by chromatography. 
There was an old precedent trying to establish a plasma fractionation plant in Brazil, 
expecting to produce albumin to rescue wound soldiers in the field, who were par-
ticipating in the Second World War in Europe. This did not happen, but later opened 
the possibility for installation of a plant fractionation by a known company, which 
did not test the plasma to produce albumin, spreading hepatitis B in Brazil. Recently, 
there was a negotiation to open Butantan plant for a public private partnership, legally 
prohibited by the Constitution. Meantime, Butantan developed a chromatographic 
process to isolate as a first step the factor VIII, following with the isolation of IgG to be 
used to control infections, which are more specific for the country [53].
6.2 Lung surfactant
Each year, about 150,000 newborn dies by suffocation few minutes after the 
delivery. Most are premature, too small, do not cry after delivery, and do not 
open the alveoli. This can be corrected by administering to the newborn a lung 
surfactant. We assemble a team of investigators, including pediatricians from the 
Medical School of the University of São Paulo, which helped to develop a process for 
isolation of natural lung surfactant from pig lungs in an enclosed system and test in 
unborn piglets just after cesarean intervention [56–60]. The project was supported 
by grants of FAPESP and by a large meat producer, which supplied the pig lungs. A 
multistate clinical trial was carried out in public maternities with very good results, 
including cases of meconium aspiration. These good results supported the drug 
registration by the national regulatory agency.
The process initially developed extracted the crude lung surfactant with the 
solvent trichloroethylene, which was removed and recovered by evaporation under 
vacuum. The final surfactant is then lyophilized. As a byproduct of the surfactant 
production, we recover aprotinin, used in the surgery to replace stands. The process 
of isolation of the lung surfactant was redesigned to use less trichloroethylene and 
guarantee full removal during freeze-drying.
A large company on meat market in Brazil showed interest in funding the new 
plant in Butantan and expects to distribute lung surfactant for free to other coun-
tries like Congo where 100,000 newborns die each year. In contrast with Brazil 
where most deliveries occur in maternities, the introduction of surfactant in some 
countries with untrained mid-wife may only administer the surfactant as aerosols 
using a portable inhaler. The use of surfactant aerosol containing tobramycin is in 
our agenda, to treat cystic fibrosis and to speed up the recovery from postinfluenza 
among elder people.
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Not all Butantan’s projects were successful, even with the partnership of impor-
tant laboratories in advanced countries. This has been the case of leishmaniosis, 
which affects Brazil and many countries in Africa and Asia. Visceral and cutaneous 
leishmaniosis infect dogs and are transmitted to man by mosquitos. It is increasing 
even in the developed state of São Paulo. New antigens are also been studied.
Difficulties are being faced also due to the reduction of funds to research insti-
tutes and even the closing of international research institutions where the develop-
ing world could find scientific support.
Butantan has proven the feasibility of public production of good quality bio-
pharmaceuticals in developing countries, contributing to world science and innova-
tion, translating the research into affordable vaccines for the population.
7. Conclusions
The Brazilian Constitution defines as role of the State to provide public health, 
specially controlling the infectious diseases where a few cases can spread the infec-
tion as epidemics to the whole population. The most effective program is to vacci-
nate, which should be affordable to the Government and then available for all.
In the early developments, advanced countries’ governments invested in focused 
research, by creating public institutes and recruiting outstanding scientists to solve 
the needs for public health. They innovate and assay their developments for efficacy 
and safety, which requires an additional step going from the lab into developing 
production technology, which lead those scientists to create large-scale production 
facilities to make biopharmaceuticals available to the society. This was not the role 
of public institutes, and soon, large companies were created to supply, not just 
the national market, but developing countries, which represent 80% of the world 
population.
Soon, the public health motivated scientists were replaced by managers that 
measure their achievements not by saving lives but by volumes of sales, not respon-
sible for public heath affordability. In recent time, producers of vaccines invested 
in innovation. Many public research institutes lost government support and some 
international health research institutes are closing. Developing countries lost sup-
port to receive technologies and to train scientists, so that they would be dependent 
forever and could not contribute to knowledge.
This brief description of scientific and industrial developments to answer to 
public health priorities represents the efforts of members of Butantan to convert 
innovation not only in publications, but also in vaccines and other biopharmaceu-
ticals at costs that the national public health system can afford. This is easy to state, 
but in most countries difficult to achieve. As Butantan was able to provide to the 
society through the government some vaccines and other biologicals at affordable 
costs, we became recognized by our population, while considered by the large 
industries in developed countries as a bad example to other developing countries, 
becoming a target to be absorbed by the international large producers, not to pro-
duce to the government but to receive bulk, fill vials, and label as local production.
Also, some of the few local producers in developing countries were purchased to 
be closed. Offers for a public private partnership were not real, as both parts did not 
plan to implement, as large pharma had no intention to transfer recent technologies, 
while the local public producers, to avoid efforts and responsibilities, replace local 
production by buying bulks at costs dictated by the real for local filing. The large 
vaccine producer changed the goals, in part by transferring the leadership from 
scientists at service of the society to skilled managers, which measure success in 
terms of sales and profit, imposing their politics to developing countries market. 
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Buying smaller pharma in developing world, in most cases does not represent local 
production at affordable prices, but simply removal of competition.
There was an attempt to buy Butantan production units. In recent years, the 
institution has been suffering political and economic interferences that led to an 
undue stop of most of the production plants, pretending to be for major renova-
tions. Instead, functional plants were destroyed, while purchasing the vaccines 
from large pharmas, without any concerns for our population or to provide afford-
able vaccines for the Ministry of Health.
Rebuilding Butantan and recover the expertise of the staff are not easy tasks and 
will require major investment. For other Latin America countries to begin without 
help is practically impossible. An interim plausible solution is to use a large unfin-
ished Butantan’s building to house a joint Latin American biotechnology center, 
while its plants are recovered to produce and train younger graduates participating 
in innovation international team, how to produce vaccines and they could take back 
with them the technologies developed at Butantan and maybe share with us clinical 
trials, avoiding the present prohibitive costs.
We think Butantan must go on with its public mission recovering good early 
Brazilian health public experiences and efforts. The case of AIDS pandemic was 
emblematic. It was partially controlled with new drugs, which were denied to poor 
countries, until Brazil challenged the patent. Same thing is in process to be repeated 
with the drug for treatment of hepatitis C, sold for $US 9000/person. And many 
other health public problems must be considered as neonatal syphilis is back to 
Brazil, even though it could be controlled with penicillin G, the first antibiotic 
discovered. The reason for the lack of penicillin is that its price became so low that 
private pharma lost interest in producing, illustrating the need of careful public 
health attention and decisions.
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